Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
Primary objective:
- To evaluate activity of imatinib mesylate and hydroxyurea among patients with
progressive/recurrent grade II low-grade glioma (LGG) as measured by 12-month
progression free survival
Secondary objectives:
- To evaluate progression-free survival (PFS), overall survival and objective response
rate among patients with progressive/recurrent grade II LGG treated with imatinib
mesylate plus hydroxyurea
- To assess safety and tolerability of imatinib mesylate + hydroxyurea in this population